TRULANCE 3 MG
PLECANATIDE : 3 MG · DIN 02493012 · BAUSCH HEALTH, CANADA INC.
Health Canada status: MARKETED
What is TRULANCE?
TRULANCE 3 MG contains PLECANATIDE : 3 MG. It is listed in the Health Canada Drug Product Database under DIN 02493012, held by BAUSCH HEALTH, CANADA INC., supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 12-Jan-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TRULANCE used for?
Treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02493012 |
|---|---|
| Brand name | TRULANCE |
| Generic / active ingredient | PLECANATIDE : 3 MG |
| Manufacturer | BAUSCH HEALTH, CANADA INC. |
| Strength | 3 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | A06AX07 PLECANATIDE |
| AHFS class | 56:92.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 12-Jan-2022 |
| Original market date | 2022-01-12 00:00:00 |
How is it administered?
Recommended dose: 3 mg orally once daily with or without food. Tablets should be swallowed whole; can be crushed in applesauce or water for patients with swallowing difficulties.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text snippet (refer to section 11 of full monograph).
How is it supplied?
White HDPE bottles of 7-count and 30-count tablets; aluminum foil unit dose blister packs of 7-count and 30-count tablets.
Contraindications
Hypersensitivity to plecanatide or any ingredient; pediatric patients less than 6 years of age; known or suspected mechanical gastrointestinal obstruction.
Warnings and precautions
Serious Warning: Risk of serious dehydration in pediatric patients. If severe diarrhea occurs, suspend dosing and rehydrate the patient.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.